$Seattle Genetics(SGEN)$
ADCs will remain an integral part of the clinical armamentarium and attractive to biopharma companies and find a footing immunooncology combination. SGEN is an ADC leader and its scienceis now extending into other arenas. Commercially Adcetris label couldexpand in 2015, 2017 and so on and clinically three or more proprietary programs are in or could be starting randomized studies with one or morewinners likely emerging